Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jaka Biotech CoBJSE:920165 20 Return-on-Tangible-Equity is 15.80% as of Jun. 2026, which is 8% below its 10-year median of 17.21. GuruFocus rates BJSE:920165 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,890 Consumer Packaged Goods companies, Jaka Biotech Co ranks better than 75.45% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Jaka Biotech Co's annualized net income for the quarter that ended in Jun. 2026 was ¥73.1 Mil. Jaka Biotech Co's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ¥462.4 Mil. Therefore, Jaka Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 15.80%.
The historical rank and industry rank for Jaka Biotech Co's Return-on-Tangible-Equity or its related term are showing as below:
BJSE:920165'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.45 Med: 17.21 Max: 21.92
Current: 17.53
During the past 4 years, Jaka Biotech Co's highest Return-on-Tangible-Equity was 21.92%. The lowest was 16.45%. And the median was 17.21%.
BJSE:920165's Return-on-Tangible-Equity is ranked better than 75.45% of 1890
companies
in the Consumer Packaged Goods industry
Industry Median: 8.1
vs BJSE:920165: 17.53
Jaka Biotech Co (BJSE:920165) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jaka Biotech Co Return-on-Tangible-Equity Related Terms
Jaka Biotech Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Jaka Biotech Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJSE:920165 vs PG, CL, EL: Return-on-Tangible-Equity Comparison
For the Household & Personal Products subindustry, Jaka Biotech Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaka Biotech Co Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Jaka Biotech Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jaka Biotech Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.80% mean?
Jaka Biotech Co (BJSE:920165) has a Return-on-Tangible-Equity of 15.80% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jaka Biotech Co and its competitors. This is near median its historical median of 17.21. Over the past decade, Jaka Biotech Co's Return-on-Tangible-Equity has ranged from 16.45 to 21.92. According to the industry distribution chart, Jaka Biotech Co ranks #464 out of 1890 companies in the Consumer Packaged Goods industry, placing it in the top 24.6%.
Is Jaka Biotech Co's Return-on-Tangible-Equity too high?
Jaka Biotech Co's current Return-on-Tangible-Equity of 15.80% is near median its 10-year median of 17.21. Over the past 10 years, this metric has ranged from a low of 16.45 to a high of 21.92. The Consumer Packaged Goods industry median Return-on-Tangible-Equity is 8.10. Jaka Biotech Co's value of 15.80% is 95.1% above this industry median. Based on the distribution chart, Jaka Biotech Co ranks #464 out of 1890 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Jaka Biotech Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Jaka Biotech Co's Return-on-Tangible-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Jaka Biotech Co ranks #464 out of 1890 companies for Return-on-Tangible-Equity. This places Jaka Biotech Co in the top 25% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.10. Jaka Biotech Co's value of 15.80% is 95.1% above this benchmark. Historically, Jaka Biotech Co's own Return-on-Tangible-Equity has ranged from 16.45 to 21.92 over the past decade. While the company's 10-year median is 17.21 vs. the industry median of 8.10, Jaka Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 8.10, based on 1,890 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jaka Biotech Co's current Return-on-Tangible-Equity of 15.80% is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jaka Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaka Biotech Co's current Return-on-Tangible-Equity is 15.80%, which is near median its own 10-year median of 17.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaka Biotech Co stock overvalued right now?
Jaka Biotech Co (BJSE:920165) has a current Return-on-Tangible-Equity of 15.80%. The current Return-on-Tangible-Equity is 15.80%, which is near median its 10-year median of 17.21 and 95.1% above the Consumer Packaged Goods industry median of 8.10. Jaka Biotech Co's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jaka Biotech Co (BJSE:920165), the current Return-on-Tangible-Equity is 15.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaka Biotech Co Ltd is engaged in the research, development, production and sales of cosmetic functional ingredients. Its operations include pharmaceutical manufacturing, testing and inspection services, manufacturing and sales of specialty chemical products, and bio-based materials.
20GF Score
Get the complete analysis for BJSE:920165
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920165 has been successfully added to your 
